Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction on Friday, December 26th. The shares were sold at an average price of $39.32, for a total value of $786,400.00. Following the completion of the transaction, the executive vice president owned 100,000 shares in the company, valued at $3,932,000. The trade was a 16.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Marshall Urist also recently made the following trade(s):

• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total transaction of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total value of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total value of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total value of $727,855.80.

Royalty Pharma Stock Down 0.4%

NASDAQ:RPRX traded down $0.14 during trading hours on Monday, hitting $39.08. The stock had a trading volume of 1,628,193 shares, compared to its average volume of 4,288,691. The company has a market cap of $22.56 billion, a PE ratio of 29.61, a price-to-earnings-growth ratio of 2.06 and a beta of 0.46. The business has a 50 day simple moving average of $38.66 and a two-hundred day simple moving average of $36.98. Royalty Pharma PLC has a 1-year low of $25.18 and a 1-year high of $41.24. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The business had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. Analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th were given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, November 14th. Royalty Pharma’s payout ratio is presently 66.67%.

Hedge Funds Weigh In On Royalty Pharma

Several institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC lifted its holdings in shares of Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 790 shares during the last quarter. USA Financial Formulas bought a new stake in Royalty Pharma in the second quarter valued at $32,000. Financial Consulate Inc. acquired a new position in shares of Royalty Pharma during the third quarter valued at $35,000. WPG Advisers LLC acquired a new position in shares of Royalty Pharma during the first quarter valued at $39,000. Finally, Larson Financial Group LLC grew its position in shares of Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 306 shares during the last quarter. 54.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RPRX shares. Morgan Stanley lowered their price objective on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 28th. Leerink Partners set a $45.00 price target on shares of Royalty Pharma in a research note on Thursday, December 11th. The Goldman Sachs Group initiated coverage on shares of Royalty Pharma in a research note on Tuesday, September 30th. They set a “buy” rating and a $42.00 price objective on the stock. Finally, Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.60.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.